Imperial College London
Portrait Picture

Prof. Diana Gorog

Faculty of Medicine, National Heart & Lung Institute

Honorary Senior Research Fellow
 
 
 
//

Contact

 

+44 (0)20 7034 8934d.gorog

 
 
//

Location

 

Royal BromptonRoyal Brompton Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Vandenbriele:2022:10.1016/j.jacc.2022.02.052,
author = {Vandenbriele, C and Arachchillage, DJ and Frederiks, P and Giustino, G and Gorog, DA and Gramegna, M and Janssens, S and Meyns, B and Polzin, A and Scandroglio, M and Schrage, B and Stone, GW and Tavazzi, G and Vanassche, T and Vranckx, P and Westermann, D and Price, S and Chieffo, A},
doi = {10.1016/j.jacc.2022.02.052},
journal = {Journal of the American College of Cardiology},
pages = {1949--1962},
title = {Anticoagulation for percutaneous ventricular assist device-supported cardiogenic shock},
url = {http://dx.doi.org/10.1016/j.jacc.2022.02.052},
volume = {79},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Interest in the use of mechanical circulatory support for patients presenting with cardiogenic shock is growing rapidly. The Impella (Abiomed Inc), a microaxial, continuous-flow, short-term, ventricular assist device (VAD), requires meticulous postimplantation management. Because systemic anticoagulation is needed to prevent pump thrombosis, patients are exposed to increased bleeding risk, further aggravated by sepsis, thrombocytopenia, and high shear stress–induced acquired von Willebrand syndrome. The precarious balance between bleeding and thrombosis in percutaneous VAD–supported cardiogenic shock patients is often the main reason that patient outcomes are jeopardized, and there is a lack of data addressing optimal anticoagulation management strategies during percutaneous VAD support. Here, we present a parallel anti-Factor Xa/activated partial thromboplastin time-guided anticoagulation algorithm and discuss pitfalls of heparin monitoring in critically ill patients. This review will guide physicians toward a more standardized (anti)coagulation approach to tackle device-related morbidity and mortality in this critically ill patient group.
AU  - Vandenbriele,C
AU  - Arachchillage,DJ
AU  - Frederiks,P
AU  - Giustino,G
AU  - Gorog,DA
AU  - Gramegna,M
AU  - Janssens,S
AU  - Meyns,B
AU  - Polzin,A
AU  - Scandroglio,M
AU  - Schrage,B
AU  - Stone,GW
AU  - Tavazzi,G
AU  - Vanassche,T
AU  - Vranckx,P
AU  - Westermann,D
AU  - Price,S
AU  - Chieffo,A
DO  - 10.1016/j.jacc.2022.02.052
EP  - 1962
PY  - 2022///
SN  - 0735-1097
SP  - 1949
TI  - Anticoagulation for percutaneous ventricular assist device-supported cardiogenic shock
T2  - Journal of the American College of Cardiology
UR  - http://dx.doi.org/10.1016/j.jacc.2022.02.052
UR  - https://www.sciencedirect.com/science/article/pii/S0735109722044849?via%3Dihub
UR  - http://hdl.handle.net/10044/1/96813
VL  - 79
ER  -
Download